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Summary Rice et al. (1986) have described a flow cytometric method where the non-fluorescent probe
monochlorobimane (mBCl) forms a fluorescent adduct with cellular glutathione (GSH) under the action of
glutathione-S-transferase. We show here that for EMT6 carcinosarcoma cells there is a close correlation
between mean cell fluorescence, expressed as a ratio to that of fluorescence calibration beads, and bio-
chemically determined GSH content over the range 0.2-2.0 fmol cell' . Single cell suspensions from 14 human
cancers were prepared by 23-gauge needle aspiration or mechanical disaggregation of surgical specimens,
stained using mBCI and examined by flow cytometry. There was a wide range in individual cell fluorescence,
which in contrast to EMT6 cells was not strongly correlated with Coulter volume. By comparing tumour cell
fluorescence to that of calibration beads, and assuming that the relationship with GSH content for EMT6
holds for other cells, a mean GSH content of 0.95 fmol cell- was derived for nine carcinomas, and 0.21 fmol
cell-' for five non-Hodgkin's lymphomas. Although this semi-quantitation needs further validation, the
method used here is rapid, gives an indication of heterogeneity of tumour cell GSH content, and can be
applied to fine needle biopsy samples. It therefore shows promise as a means for studying prospectively the
relationship of GSH content to clinical drug and radiation sensitivity, and for monitoring the effects of agents
such as buthionine sulphoximine which are intended to improve treatment results through tumour cell GSH
depletion.
lonising radiation and a variety of clinically useful cytotoxic
drugs produce reactive free radicals capable of interacting
with essential cellular macromolecules, particularly DNA.
The ubiquitous sulphydryl-containing tripeptide glutathione
can protect from this damage by scavenging free radicals,
either spontaneously or when catalysed by one of the glu-
tathione-S-transferase isoenzymes. It can in addition reduce
hydrogen peroxide or disulphide bonds by undergoing an
oxidation/reduction cycle under the actions of glutathione
peroxidase and glutathione reductase (Meister & Anderson,
1983). Glutathione is an abundant molecule in cells, cytoplas-
mic concentrations being typically in the millimolar range,
and there is increasing evidence that elevated tumour cell
GSH or glutathione-S-transferase activity could be an impor-
tant cause of radiation and alkylating agent resistance in
cancer patients. In particular, resistant cell lines often show
an elevated GSH content, while pre-treatment of tumour-
bearing animals with buthionine sulphoximine (BSO), which
reduces GSH content by blocking gamma-glutamyl-cysteine
synthetase, can improve the therapeutic index of alkylating
agents (Ozols et al., 1987; Lee et al., 1987; Skapek et al.,
1988). Although there is an extensive literature examining
GSH and drug or radiation resistance in vitro and in tumour-
bearing animals, relatively little has been published about
GSH content of human cancers. Furthermore, standard bio-
chemical or HPLC assays of GSH content give mean values,
whereas heterogeneity of individual cell GSH content may be
of great importance. For example, two tumours with iden-
tical mean cell GSH content might show different radiation
sensitivities if one contained a minor population with greatly
increased levels.
Flow cytometry is emerging as a powerful method for
studying tumour cell populations. Major advantages include
the small sample size required, rapidity of most assays and
the ability to study heterogeneity of cell populations. A
number of flow cytometric methods for measuring cellular
GSH content have been described, all of them depending on
the binding of a fluorescent ligand to the sulphydryl group.
Of the available probes, monochlorobimane (mBCl) is prob-
ably the best characterised and most specific for GSH be-
cause its rate of binding is said to be 1,000-fold enhanced by
glutathione-S-transferase, allowing use of stain concentra-
tions too low to cause significant non-specific binding to
other sulphydryl-containing compounds (Rice et al., 1986;
Shrieve et al., 1988).
This paper describes an evaluation of the mBCI FCM
method for studying human cancer, particularly using fine
needle aspirates which can be readily and non-traumatically
obtained in the clinic. Results show considerable hetero-
geneity in cell fluorescence, with carcinomas having
significantly higher mean values than lymphomas. Although
this method is probably dependent on a number of enzyme
activities in addition to cell GSH content, preliminary data
are presented to suggest that the FCM method can be made
semi-quantitative by reference to a standard biochemical
assay of GSH.
Materials and methods
Cell culture
EMT6 mouse carcinosarcoma cells were grown as mono-
layers in RPMI-1640 tissue culture medium supplemented
with 10% fetal calf serum. They were set up in 25 cm2 flasks,
and cell glutathione variably depleted by the addition of
50fLM L-buthionine sulphoximine (Sigma, St Louis, MO,
USA) for 4 or 6 h, either during exponential growth or at
confluence.
Glutathione assay
Cells were removed from the monolayer using trypsin plus
EDTA, washed and counted. They were adjusted to
I x 106ml-' and resuspended in 0.6% sulphosalicylic acid
for 60 min at 0°C. Insoluble material was removed by cent-
rifugation, and GSH content of the supernatant measured
using Eyer and Podhradsky's modification (1986) of the
method of Tietze (1969). This involves reduction of the
aromatic disulphide 5,5'-dithiobis(2-nitrobenzoic acid)
(DTNB) to the chromogenic TNB by GSH, which is oxidised
to its disulphide-linked dimeric form GSSG. In order to
maintain the reaction, GSSG is reduced back to GSH by
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addition of glutathione reductase and NADPH. After
equilibration at room temperature the reaction was started
by the addition of glutathione reductase, and the linear in-
crease in absorbence at 412nm seen using the test sample
compared to that obtained using a standard containing re-
duced GSH. Results were expressed as fmol GSH per cell.
Flow cytometry
Monochlorobimane (mBCI, Molecular Probes, Eugene,
OR, USA) was made up at 1 mM in 100% ethanol, and
stored at -20°C. Cells were suspended at 1 x 106ml-' in
fresh tissue culture medium and stained using mBCI at
various concentrations at 20°C for 2.5-30 min. Flow cyto-
metry was done using a FACS Analyzer (Becton-Dickinson,
Mountain View, CA, USA). This instrument uses a mercury
arc lamp as the light source, and is capable of simultaneous
measurement of cell fluorescence and Coulter volume. The
strong 360-380 nm ultraviolet emission from the arc lamp
was selected using a UGI excitation filter, with a 480-500
bandpass filter being used for emission. Alignment was done
using 9 ,tm diameter Hoechst-33342 stained calibration beads
(Flow Cytometry Standards Corporation, Research Triangle
Park, NC, USA), and fluorescence intensity expressed as
channel numbers, which are arbitrary units on a linear scale.
Immediately following the calibration beads, and using the
same instrument settings, unstained cells were run to record
autofluorescence, followed by the mBCI-stained cells, which
were run in the presence of stain. A minimum of 30,000
stained cells was run, and mean cellular fluorescence (minus
mean autofluorescence) recorded.
Clinical samples
A total of 14 clinical samples were examined. Seven of these
were obtained by 23 gauge needle aspiration from patients
who gave verbal informed consent for the procedure, one
consisted of peripheral blood lymphoblasts separated by den-
sity-gradient centrifugation from a patient with end-stage
T-cell acute lymphoblastic leukaemia, and the remainder
were fresh surgical specimens which were mechanically disag-
gregated using crossed scalpel blades. Cell suspensions were
filtered through gauze, washed and counted. If necessary,
clumps were dispersed by syringing through 25 gauge
needles. After adjusting to a final concentration of
I x 106ml-', cells were filtered through 70 tm plankton net-
ting and stained using 40 JiM mBCI for exactly 5 min at 2O°C.
Flow cytometry was done exactly as for cultured cells, except
that the machine was triggered on Coulter volume, set at a
threshold level of 300 jtm3 to exclude red blood cells and
cellular debris. In addition to fluorescence, the ratio of cell
fluorescence to Coulter volume was obtained using the elect-
ronics of the FACS Analyser.
Results
Monochlorobimane staining ofEMT6 Cells
The effects of mBCI concentration and time on the staining
intensity of EMT6 cells are shown in Figure 1. There was a
rapid initial increase in fluorescence, the rate slowing after
approximately 15 min. Using 5 or 10 lmmBCl staining in-
tensity then decayed, while with higher concentrations it
slowly increased up to 30 min. Shrieve et al. (1988) have
previously shown that when EMT6 cells are stained with
40 laM mBCI for 5 min, fluorescence intensity is closely cor-
related with biochemically determined GSH content, because
the staining reaction is strongly catalysed by glutathione-S-
transferase. We were able to confirm that >99% ofcytoplas-
mic fluorescence was of low molecular weight by sonicating
EMT6 cells stained with mBCI under the above conditions,
fractionating with a Sephadex G25 column, and measuring
fluorescence using a spectrofluorimeter. Furthermore, fluores-
cent material was eluted off the column in the same fractions
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Figure 1 Effects of time and concentration on mean fluorescence
of EMT6 cells stained with monochlorobimane at 20°C. Indicated
monochlorobimane concentrations are micromolar.
as a GSH-mBCl adduct pre-formed by reacting equimolar
concentrations of the two compounds non-enzymatically. In
contrast, when the more reactive GSH probe monobromo-
bimane was substituted for mBCI, approximately 8% of
cytoplasmic fluorescence was present in high molecular
weight fractions.
Biochemical assay ofGSH
The biochemical assay for GSH gave typical mean values of
3-4 fmol per EMT6 cell during exponential growth, falling
to approximately 2 fmol cell-' when the cells were grown to
high densities. This fall was not simply due to a reduction in
cell volume, which had a mean value of approximately
3,900,Im3 during logarithmic growth, and 3,500IUm3 at high densities. Although treatment with 50 SOM BSO for 6 h re-
duced the GSH content of exponentially growing cells by only approximately 50%, it was observed that similar treat-
ment of the high density cells could yield mean GSH levels as
low as 0.1 fmol cell-'. The explanation for this apparently
enhanced sensitivity to BSO at high density growth is unc-
lear, but preliminary experiments suggest that it is not the
direct result of medium exhaustion or acidification.
Comparison ofmBClfluorescence and GSH assay
The relationship between FCM-determined fluorescence of
EMT6 cells stained with 40t.M mB3CI for 5 min, and for cells
from the same culture flask assayed for GSH is shown in
Figure 2. Results for GSH contents of <3.0 fmol cell-' give
a close linear fit intercepting almost at the origin (correlation
coefficient = 0.969). Using this relationship, it can be seen
that individual 9 jm calibration beads have a fluorescence
equal to that of a GSH content of 0.83 fmol in an EMT6 cell
stained with 40 laM mBCI for 5 min at 20°C. Note that for
cell GSH contents > 3.0 fmol cell-' (and possibly >2.0 fmol
cell-') this linear relationship between fluorescence and GSH
content does not hold. FCM tending to underestimate GSH
content.
FCM measurement ofGSH in human cancer biopsies
Of the patients studied, five had non-Hodgkin's lymphomas,
four being diffuse large cell and one T-cell lymphoblastic
lymphoma in terminal leukaemic phase. With the exceptionGLUTATHIONE CONTENT OF HUMAN CANCER 67
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Figure 2 Correlation between mean fluorescence of mBCI-
stained EMT6 cells and their glutathione content determined
using a biochemical assay. The range in GSH content was ob-
tained by depletion using BSO. Fluorescence is expressed as a
ratio to that of 9fLm Hoechst-33342 stained calibration beads.
The linear regression line excludes samples of GSH content
greater than 3.0 fmol cell-'.
of one patient with diffuse large cell lymphoma, all had
recurrent disease following previous chemotherapy. There
were nine solid tumours (two non-small lung, two cervix and
one prostate, breast, endometrium, ovary and mesothelioma).
Only two of these patients had received prior chemotherapy.
Cells were stained using 40JM mBCI for 5 min at 20°C.
Because cell suspensions from human tumour biopsies con-
tained large amounts ofdebris and red blood cells, the FACS
Analyser was triggered on Coulter volume with a threshold
set at 300 fim3.
Measurement of individual cell fluorescence showed con-
siderable heterogeneity. In contrast to EMT6 cells, where
fluorescence intensity was roughly proportional to cell size,
there was no obvious relation between Coulter volume and
mBCI staining (Figure 3). Indeed, in many cases those cells
C.A. Breast-FNAB
with the greatest volume showed only weak fluorescence,
indicating that this wide range of values was not due to the
presence of cell clumps. Restaining the sample illustrated in
Figure 3 for cellular DNA content showed that approx-
imately 90% of the cells were aneuploid, i.e. there was
minimal contamination with normal host cells.
The relative fluorescence of the calibration beads was re-
corded immediately before running each of the clinical sam-
ples, and because these were stained under identical condi-
tions to the EMT6 cells, the relationship between fluor-
escence and GSH content shown in Figure 2 was used to
approximate mean GSH content of the tumour biopsies. This
gave a mean value of 0.21 ± 0.12 fmol cell-' for the lym-
phomas, and 0.95 ± 0.39 for the solid tumours. Scatter of
mean values is shown in Figure 4. Note that all samples were
well within the linear part of the fluorescence/GSH content
plot for EMT6 cells.
Discussion
The ubiquitous presence of large amounts of GSH in cells
reflects the need to detoxify free radicals generated by, for
example, incomplete reduction of molecular oxygen or by
certain xenobiotics. Because many anti-cancer agents mimic
the actions of these natural threats to cells, it is not surpris-
ing that GSH and its related enzymes are implicated in
clinical drug or radiation resistance. Interestingly, there is
now evidence linking increased GSH-S-transferase or GSH
peroxidase activities to enhanced mdr gene expression
(Kramer et al., 1988), and to capacity for DNA repair (Deffie
et al., 1988), suggesting that multifactorial cancer cell resis-
tance could simply be the recruitment of a multi-layer de-
fence system which evolved to protect macromolecules from
common environmental hazards.
Despite an extensive literature examining the role of GSH
in drug or radiation resistance in experimental model sys-
tems, surprisingly little has been published concerning fresh
human cancer specimens. It would be important to determine
the extent to which tumour cell GSH content caused clinical
drug or radiation resistance, because methods for overcoming
this have been proposed. In particular, GSH depletion using
BSO can improve the therapeutic index of alkylating agents
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Figure 3 Flow cytometric measurement of cellular glutathione
content in a fine needle aspiration biopsy from a breast car-
cinoma. Top left indicates Coulter volume, threshold set at
300 ;m3 to exclude debris and red blood cells. Top right is
glutathione content in arbitrary units on a linear scale. The
correlated dot plot shows that the wide range in GSH content is
not a simple function of cell size, the largest cells having rela-
tively weak fluorescence. Subsequent cellular DNA content analy-
sis showed that approximately 90% of cells were aneuploid,
indicating that this heterogeneity did not result from contamina-
tion by normal host cells.
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Figure 4 Estimated mean glutathione content of human cancer
biopsies. Values were obtained by comparing mean cell fluor-
escence to that of 91Am Hoechst-33342 stained calibration beads,
and assuming that the linear relation between this and actual
GSH content obtained for EMT6 cells holds for the clinical
material.
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used to treat human tumour xenografts, and phase 1 trials of
BSO in cancer patients are underway.
Measurement of GSH using mBCl is an unusual FCM
method, because its specificity depends on GSH-S-transferase
combining it to GSH rather than to other sulphydryls.
Recent evidence (Cook et al., 1989) would suggest in fact
that for at least some cell lines this, rather than GSH con-
tent, determines mBCI fluorescence. Cellular GSH turns over
quite rapidly, and GSH feedback inhibits its own synthesis.
Following reaction with an electrophile, GSH can be deg-
raded, and its constituent amino acids recycled (Meister &
Anderson, 1983). The complex time and concentration de-
pendence of EMT6 cells illustrated in Figure 1 probably
reflects these processes, since the act of staining cells with
mBCl would be expected to cause depletion of target mole-
cule. The higher concentrations of mBCI used exceed the
total GSH content of the cell sample by several fold, and
might therefore stimulate resynthesis as they deplete cells of
existing GSH. Rice et al. (1986) showed that following its
depletion by diethylmaleate, GSH content of EMT6 cells
approximately doubled every 60 min. In contrast, the lower
concentrations of mBCI might become exhausted as the
GSH-mBCl adduct is degraded. It seems possible therefore
that the assay is giving an overall picture of a cell's ability to
cope with a reactive chemical species rather than simply
measuring GSH. A more detailed picture of the processes
involved might be obtained by the additional use of other
sulphydryl stains such as mercury orange (O'Connor et al.,
1988), which, although probably less specific for GSH, stains
non-enzymatically at 4°C. Despite the fact that an unusual
dependence on a number of enzymes means that equilibrium
between fluorochrome and target molecule is probably never
achieved, EMT6 cells stained for 5 min using 40ILMmBCI
had a mean fluorescence which correlated closely with bio-
chemically determined GSH content over the range 0.2-
-2.0 fmol cell-'. We have linked this correlation to the
fluorescence of calibration beads, and subsequently used
these beads as a tentative standard to quantitate clinical
samples. The results show mean tumour cell GSH contents
similar to those obtained using standard assays, with solid
tumours having significantly higher values than non-Hodg-
kin's lymphomas. It should be emphasised that a large series
comparing flow cytometry of human cancer biopsies (rather
than EMT6 cells) with a standard GSH assay would be
required in order to establish the reliability of quantitative
FCM results. Nevertheless, we believe that the data shown
here are of interest because they demonstrate a wide range in
individual tumour cell GSH content which is not a simple
function of cell size. The assay can be performed rapidly
using fine needle aspirates, thus considerably extending its
clinical scope by, for example, allowing sequential measure-
ments to be made during treatment with agents designed to
modulate cellular GSH. Under the latter circumstances exact
quantitation of GSH may in fact be less critical, since results
could be related to pre-treatment values. Although these
results are preliminary, they suggest an emerging role for
flow cytometry as an aid to active cancer patient manage-
ment, in addition to its more defined place as an adjunct to
diagnostic pathology.
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